In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Armata Pharmaceuticals (ARMP – Research Report), with a price target of $7.00. The company’s shares closed yesterday at $4.25.
According to TipRanks, Pantginis is an analyst with an average return of -20.3% and a 29.84% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Astria Therapeutics, Alpine Immune Sciences, and PDS Biotechnology.
Armata Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $8.00.
See the top stocks recommended by analysts >>
Based on Armata Pharmaceuticals’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $8.77 million. In comparison, last year the company had a GAAP net loss of $5.5 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. Its product candidate is the AP-SA01 that targets Staphylococcus aureus, including multidrug-resistant strains. The company was founded on May 9, 2019 and is headquartered in Los Angeles, CA.
Read More on ARMP:
- Analysts Offer Insights on Healthcare Companies: Medios AG (OtherMEDOF), Spectrum Pharmaceuticals (SPPI) and Fortress Biotech (FBIO)
- Analysts Offer Insights on Technology Companies: Leaf Mobile Inc (OtherEAGRF) and N-able (NABL)
- Harsco Corporation Announces Chief Financial Officer Transition
- Director/PDMR Shareholding
- H.C. Wainwright Reaffirms Their Buy Rating on Avino Silver & Gold (ASM)
